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Abstract
Background
Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan para-
sites of the genus Leishmania. CL causes enormous suffering in many countries worldwide.
There is no licensed vaccine against CL, and the chemotherapy options show limited effi-
cacy and high toxicity. Localization of the parasites inside host cells is a barrier to most stan-
dard chemo- and immune-based interventions. Hence, novel drugs, which are safe,
effective and readily accessible to third-world countries and/or drug delivery technologies
for effective CL treatments are desperately needed.
Methodology/Principal Findings
Here we evaluated the antileishmanial properties and delivery potential of polyhexamethy-
lene biguanide (PHMB; polyhexanide), a widely used antimicrobial and wound antiseptic, in
the Leishmaniamodel. PHMB showed an inherent antileishmanial activity at submicromolar
concentrations. Our data revealed that PHMB kills Leishmania major (L.major) via a dual
mechanism involving disruption of membrane integrity and selective chromosome conden-
sation and damage. PHMB’s DNA binding and host cell entry properties were further
exploited to improve the delivery and immunomodulatory activities of unmethylated cyto-
sine-phosphate-guanine oligodeoxynucleotides (CpG ODN). PHMB spontaneously bound
CpG ODN, forming stable nanopolyplexes that enhanced uptake of CpG ODN, potentiated
antimicrobial killing and reduced host cell toxicity of PHMB.
Conclusions
Given its low cost and long history of safe topical use, PHMB holds promise as a drug for CL
therapy and delivery vehicle for nucleic acid immunomodulators.
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Author Summary
Intracellular pathogens are difficult to kill because their localization inside host cells pro-
vides protection against immunity and chemotherapies. Thus, successful treatment of dis-
eases caused by intracellular pathogens may need combination therapies and effective
delivery systems. Cutaneous leishmaniasis (CL) is caused by intracellular protozoan path-
ogens of the genus Leishmania. CL is a long established global problem, yet there are no
suitable vaccine or chemotherapy options. We found that the well-tolerated cationic poly-
mer PHMB is able to directly kill Leishmania major (L.major) and to enhance host-
directed killing by improving the delivery of immunomodulatory nucleic acids. The study
exemplifies parallel host- and pathogen-directed killing of an intracellular pathogen in the
presence of effective drug delivery platforms. This general strategy holds great promise for
therapy of a range of diseases caused by intracellular pathogens.
Introduction
Leishmaniasis has persisted for centuries as a life-threatening and disfiguring disease,
endemic to 98 countries across the globe, with an overall estimated prevalence of 12 million
and a yearly incidence of 2 million new cases [1,2]. It mainly affects the poorest regions of
the world, where patients cannot afford medication. It is also endemic in several developed
countries including France and Spain, and there are reports of increasing cases of leishmania-
sis in developed countries, where the disease is considered non-endemic [3,4]. Leishmaniasis
is classically subdivided into three main clinical forms: cutaneous, mucocutaneous, and vis-
ceral. Two thirds of all cases worldwide are cutaneous leishmaniasis (CL) presentations
[2,5,6]. CL symptoms range from single, self-healing cutaneous wounds to a persistent, meta-
static disease [7]. The basis for such diverse pathologies is multifactorial and complex, and
innate immune system functioning and its pattern recognition receptors are determining
factors [7,8]. Thus, host immunity is a decisive factor that influences the outcome of Leish-
mania infection. Furthermore, Leishmania parasites manipulate and subvert host immune
responses. For example, L.major infection shifts cellular immunity, associated with cytokines
such as interleukin (IL)-12, interferon gamma (IFN-γ) and tumor necrosis factor (TNF)-α
producing Th1 CD4+ T lymphocytes, to humoral immunity, associated with (Th2) CD4+ T
lymphocytes responses in susceptible hosts [9–11]. Conversely, the host immune deviation
towards Th1 results in effective removal of the parasite from the host, and is a promising
approach for intracellular pathogen therapy.
CL is a neglected tropical disease, and medicine does not provide a suitable therapy. The
available treatments are old and the systemic side effects often outweigh any clinical benefits
[12,13]. After decades of research in drug development, there is still no new commercial drug
for treatment of CL. Most patients in the affected regions are poor and cannot afford medica-
tion, discouraging pharmaceutical industry investment. Alternative treatment approaches that
are safe, effective and readily accessible to third-world countries are of major interest. Among
several drug discovery strategies, repositioning existing drugs from other areas of disease is
considered to be a cost-effective strategy and accounts for many currently used anti-parasitic
drugs, and thus, has historically played an important role in anti-parasitic drug development
[14]. For example, amphotericin B, miltefosine and paromomycin have all been repositioned
to treat leishmaniases.
The current treatment regimens against CL can be either local or systemic. The choice of
systemic versus local therapy is based on the causative Leishmania subspecies, geographic
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regions, severity of the diseases and the patient’s immune status [15,16]. Complex cases such
as patients having more than three lesions, singular lesion measuring> 40 mm in diameter,
lesion in cosmetically and functionally delicate body parts (such as face, joints, mucocutane-
ous zones, lymph nodes) and immunosuppressed patients should be treated systemically
[16]. Parenteral administration of antimonials, pentamidine, amphotericin B or oral miltefo-
sine is the standard systemic treatment against CL. However, their efficiencies are limited by
several factors, including significant toxicity and other side effects [2,3,15,17]. Local treat-
ment such as paromomycin ointment and infiltration with antimonials has been recom-
mended by the World Health Organization (WHO) as a first line treatment for non-
complicated CL cases [2]. Although local treatments offer significant advantages over sys-
temic therapy, they have not yet displayed a strong and consistent effect. Overall, there is a
lack of evidence for potential benefit of the current CL treatments. Insufficient killing of
stealth parasites inside macrophages and insufficient drug concentrations within the dermis
are factors that appear to hinder its clinical use [18,19], suggesting a need for improved drug
delivery, absorption and retention strategies. Importantly, it has been shown that liposomes
loaded with drugs enhance in vitro drug permeation across stripped skin and improves the in
vivo antileishmanial activity in experimentally infected mice [12,20,21]. Also, modulation of
the immune micro-environment for host-directed treatment against CL has been suggested
as a potential therapeutic and prophylactic strategy [22]. Indeed, immune modulation
towards Th1 responses using immune modulating agents such as CpG ODN showed promis-
ing efficacy against leishmaniasis [23–25]. A further advantage is that CpG ODN can acceler-
ate wound repair [26,27]. Similarly, it has been shown that topical application of an
immunomodulator imiquimod assists CL wound healing [21,28]. Therefore, an improved
formulation of CpG ODN could stabilize oligomers against degradation, enhance cell uptake,
increase killing within macrophages and aid wound repair.
PHMB is a synthetic cationic polymer recommended as a first-choice treatment for
locally infected and critically colonized wounds [29]. PHMB has inherent antimicrobial
effects and is used to treat certain parasite infections, but there are no reports of its use
against intracellular pathogens or Leishmania species. As well as providing direct antimi-
crobial effects, PHMB may be able to mediate delivery of other therapeutics. Several syn-
thetic and natural cationic polymers are used as nucleic acids carriers by forming polyplex
(any complex of a polymer and nucleic acids) nanostructures through their ability to con-
dense nucleic acids into particles, while allowing dissociation once inside the cell [30,31].
Therefore, PHMB has the potential for dual use against infections, providing both direct
pathogen killing and enhanced delivery of nucleic acids that can modify the immune system
to enhance killing.
Here we aimed to investigate the potential use of PHMB as an antileishmanial agent and as
a non-viral nucleic acid carrier of CpG ODN. We found that PHMB itself has potent leishma-
nicidal activity at submicromolar concentrations. PHMB’s leishmanicidal mechanisms of
action appear to involve disruption of parasite cell membranes, cell entry and condensation/
disruption of parasite chromosomes. Also, we found that PHMB spontaneously binds CpG
ODN and forms stable nanopolyplexes by interacting with CpG ODN at appropriate dose
ratios. PHMB also protects and prompts cellular uptake of CpG ODN. Interestingly, the nano-
polyplexes effectively counteract the toxicity associated with PHMB by interacting with nega-
tively charged CpG ODN through charge complexation/shielding. Therefore, PHMB/CpG
ODN can provide combined host- and pathogen-directed leishmanicidal effects against CL
and may provide multiple benefits for CL therapy.
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Methods
Cell culture
BMDMwere generated from the bone marrow of BALB/c mice (Charles River Breeding Labora-
tories, Sulzfeld, Germany) and cultured for 6 days at 37°C and 5% CO2, as recently described
[32]. The primary BMDMwere then harvested and maintained in phenol-free complete Roswell
Park Memorial Institute (RPMI) medium containing 10% fetal calf serum (heat-inactivated at
56°C for 30 min), 2 mM L-glutamine, 10 mMHEPES buffer, 0.05 mM β-mercaptoethanol solu-
tion, gentamicin (50 μg/ml) and penicillin G (100 u/ml) for all experiments. The same media
were used in L.major parasites experiments. 293T kidney epithelial cells (DSMZ-No ACC-635,
Braunschweig, Germany) were cultivated and maintained in high glucose (4.5 g/l) DMEMwith-
out L-glutamine and phenol red but containing 10% fetal calf serum (heat-inactivated), 200 mM
L-glutamine and sodium pyruvate. Human adult calcium temperature (HaCaT, keratinocytes)
were obtained from Dr. Amir Sharili, Queen Mary University of London. Keratinocytes were cul-
tivated in DMEM containing 10% fetal bovine serum, with 4.5 g glucose/l, 0.11 g sodium pyru-
vate/L and L-glutamine 0.584 g/l.
AlamarBlue assay
Cytotoxicities of the different compounds or formulations against mammalian cell (BMDM or
293T epithelial cells) and L.major promastigotes were determined as previously described
[33]. Briefly, 4 × 104 mammalian cells or 10 × 106 virulent L.major promastigotes (MHOM/IL/
81/FE/BNI strain) in the log phase of growth were added to each well of 96-well plates and
cultured with five increasing concentrations of each compound at 37°C or 27°C for 24 h,
respectively. Standard antileishmanial drugs including amphotericin B (A2942), pentamidine
isothionate (P0547) and paromomycin sulfate (P9297) from Sigma-Aldrich (Deisenhofen, Ger-
many) and miltefosine (1-hexadecylphosphorylcholine) (Cayman Chemical Company, Ann
Arbor, MI, USA) were used as positive controls. The AlamarBlue dye (Trinova Biochem
GmbH, Giessen, Germany) was added to each well at 10% concentration and incubated for a
further 48 h. The optical density (OD) was then measured by using Multiskan Ascent ELISA
reader at a wavelength 550 nm and 630 nm. The OD value or % dye reduction is proportional
to viable cell/parasite number and was used for IC50 calculation based on the intercept
theorem.
Luciferase reporter assay (amastigote assay)
The assay is based on bioluminescence measurement of firefly luciferase, which catalyzes the
formation of light from ATP and luciferin. The virulent luciferase-transgenic (Luc-tg) L.major
strain containing a firefly luciferase reporter gene was maintained by continuous passage in
female BALB/c mice and was grown in 96-well blood agar cultures at 27°C, 5% CO2, and 95%
humidity. A luciferase-transgenic L.major strain was used to infect BMDM according to our
recently established protocol [34]. Briefly, BMDM numbers were adjusted to 2 × 105, cultured
in 96-well plates and incubated for 4 h to allow adherence to the surface. The promastigote
number was adjusted to 3 × 106 parasites per ml to achieve an infection rate of 1:15. Then,
infection was made by discarding the supernatant of the cultured cells and replacing it with an
equal volume of complete RPMI medium containing the promastigotes' suspension. After
incubating the infected BMDM (37°C, 5% CO2) for 24 h to allow full differentiation of the pro-
mastigotes into amastigotes, the medium containing the extracellular parasites was removed
and the wells were washed three times with the same RPMI medium. Five serial dilutions of
each substance (1:5) in the same fresh RPMI medium were added to the infected BMDM in
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duplicate with the appropriate controls. After further 24 h of incubation at 37°C and 5% CO2,
the infected BMDM were lysed with a luciferin-containing buffer (Britelite, PerkinElmer, Ger-
many) and luminescence was measured with a luminescence plate reader, Victor X Light 2030
luminometer (PerkinElmer). The IC50 values of the compounds against intracellular amasti-
gotes were calculated based on the intercept theorem, as previously described [34,35].
Flow cytometry
PI and YO-PRO-1 dyes (Life Technologies, Darmstadt, Germany) uptake by the promastigotes
was measured by MACS Quant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany), and
used to indicate membrane integrity [36]. YO-PRO-1 dye selectively passes through the plasma
membranes of apoptotic cells but it does not label living cells [36]. L.major promastigotes were
treated with 2 μM PHMB for indicated time points and then washed at 3,000 × g for 10 min.
The samples were stained by incubating with PI or YO-PRO-1 dyes for 15 min in the dark at
RT according to manufacturer’s instructions. The samples were then washed and a total of
100,000 events were immediately acquired by flow cytometry. Similarly, adherent BMDM cells
were allowed to take-up fluorescent PHMB (PHMB-FITC conjugate) in the presence or
absence of five different pharmacological inhibitors (cytochalasin D (C8273, used at 5 μg/ml),
wortmannin (W1628, used at 12.85 μg/ml), chlorpromazine hydrochloride (C8138, used at
10 μg/ml), ikarugamycin (SML0188, used at 1 μM) and dynasore (D7693, used at 25.8 μg/ml),
Sigma-Aldrich, Deisenhofen, Germany). PHMB (Polyhexamethylene biguanide; CAS#
27083-27-8; alternative chemical names: polyhexanide, polyamino propylbiguanide, Mw =
2780 g/mol) [37] was provided by the laboratory of Dr. Liam Good and by Tecrea Ltd, London
UK (www.tecrea.co.uk), at stock concentrations of 1 mg/ml and 200 mg/ml. PHMB is a cat-
ionic and amphipathic structure composed of repeating basic biguanidine units connected by
hexamethylene hydrocarbon chains. The structure and concentrations of PHMB as % weight/
volume are shown in the supplementary information (S1 Fig and S1 Table). PHMB
(PHMB-FITC) was produced according to recently developed method (further details will be
provided in a separate publication, Chindera et al., submitted). Briefly: 2 mg of fluorescein iso-
thiocyanate (FITC) was dissolved in dimethylformamide that contains 50 μl of N,N-diisopro-
pylethylamine. The solution was then mixed with 50 mg of PHMB in 200 μl volume and
shaken overnight at RT. The resulting mixture was dialyzed using molecular weight cut off
membrane 3.5 kDa against 50% aqueous ethanol for 5 days with intermittent change of dialy-
sate and lyophilized to obtain fluoresceinyl‐PHMB (PHMB‐FITC). Moreover, polyplexes were
prepared between PHMB and 3’ end rhodamine red-labeled CpG ODN (CpG-R) (Mw = 6891
g/mol, sequence TCCATGACGTTCCTGATGCT, Eurofins MWGOperon, Germany) at
1:1 (w/w) ratio for uptake study. The poylplexes and CpG-R were incubated with BMDM in
the absence or presence of the endocytosis inhibitors for various time points. The BMDM were
harvested, washed, diluted to 1 × 106 and a total of 20,000 events were acquired per sample by
flow cytometry. The data were analyzed using FlowJo software (Tree Star Inc., CA, USA).
Fluorescence microscopy and confocal microscopy
The BMDM or promastigotes were co-cultured with the indicated doses of fluorescent PHMB
for 24 h or 48 h. The samples were transferred to 15-ml tubes, washed and fixed with 4% para-
formaldehyde. The DNA of L.major promastigotes and BMDM were counterstained with
Hoechst 33342 (Life Technologies, H3570, Darmstadt, Germany). Finally, 10 μl of the solution
containing the parasites or BMDM were added to slides and covered with cover slips for micro-
scopic examinations. Images were obtained using live video fluorescence and confocal micros-
copy systems (Wetzlar, Germany).
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Electrophoretic mobility shift assay (EMSA)
Genomic DNA was isolated from 1.5 × 109 L.major promastigotes using Purelink Genomic
DNA kit (K1820-01, Life Technologies, Germany) and was quantified by using a NanoDrop
2000 spectrophotometer (Thermo Scientific, Germany). PHMB/gDNA polyplex formulations
were prepared by adding and mixing 4.5 μg of gDNA with PHMB (0–54 μg) in a final volume
of 30 μl water. Similarly, PHMB/CPG ODN or PHMB/CpG-R polyplexes were prepared by
mixing 30 μg CpG ODN 1668 (Mw = 6058 g/mol, sequence TCCATGACGTTCCTGATGCT,
Eurofins MWGOperon, Germany) or 15 μg of CpG-R with PHMB (0–54 μg) in a final volume
of 30 μl water, respectively. After thorough mixing by pipette, the polyplexes were left at room
temperature for 2 h prior to analysis. The samples were then combined with 6× Blue/Orange
loading dye (Promega, Germany) and loaded onto a 1% agarose gel containing SYBR gold
nucleic acid gel stain (S11494, Life Technologies, Germany) for electrophoresis.
Transmission electron microscopy
Transmission electron microscopy (TEM) was used to determine particle sizes, and character-
ize stability and morphology of PHMB/CPG ODN polyplexes. For stability testing, polyplexes
were prepared by mixing PHMB and CpG ODN at a 2:1 (w/w) ratio and kept at 4°C for two
months. The samples were then mounted on 300-mesh grids, stained with uranyl acetate and
lead citrate, analyzed with TEM (JEOL JEM-2100, Germany) operated at 80 kV and 200 kV
with TVIPS F416 4k x 4k and Olympus Veleta 2k x 2k camera systems and imaged at 4400 or
12,000 x magnification.
Dynamic light scattering (DLS) and electrophoretic light scattering (ELS)
The particle sizes and zeta potential of PHMB/CpG ODN polyplexes were measured by using a
Beckman coulter Delsa Nano C (Beckman Coulter, Krefeld, Germany). The CONTIN analysis
mode and the Smoluchowski equation were used to determine the size and the Zeta potential,
respectively. The measurements were done in triplicate and reproduced at least twice. The size
and zeta potential measurements were performed in clean disposable cuvettes containing
500 μl Millipore Water or ionic strength adjusted (ISA) water (KCl 0.15M) and PHMB/CpG
ODN polyplexes at a ratio of 2:1 or 1:1 (w/w). The average particle size distributions of the
polyplexes with their polydispersity index (PDI) and zeta potential values were determined by
DLS and ELS. All measurements were carried out at 25°C. Scattered light was detected in an
angle of 165° (particle size) and 15° (zeta potential).
Isothermal titration calorimetry (ITC)
Affinity and specificity of interactions between PHMB and CpG ODN were studied by directly
measuring the heat released or absorbed during binding events with MicroCal iTC200 System
(GE Healthcare Northampton, MA, USA). All the samples were diluted in Millipore Water
and degassed by ultrasonication for 15 min prior to their use. A 40-μl microsyringe was filled
with 0.3 mM PHMB and injected at a rate of 2 μl/injections into cell samples containing 200 μl
of 0.03 mM CpG ODN for a total of 20 individual injections. The titrant syringe functions
as the stirrer at a speed of 400 rpm. The stabilization delay of the heat signal before the first
injection was 3 min. The injection interval was 150 seconds and a calibration power of
5 ± 0.5 μcal/sec was used. The measurements were performed in triplicate at 25°C. The back-
ground heat was determined by titrating Millipore Water into CpG ODN and was subtracted
from the main experiment. All data were automatically collected and analyzed using Origin
PHMB-Mediated Pathogen- and Host-Directed Therapy
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and SigmaPlot Software to determine the thermodynamic parameters. The binding isotherm
(ΔH) was used for fitting to an appropriate model.
Determination of cytokine productions
BMDM were generated from female BALB/c mice as described above in cell culture. 1 × 106
BMDM were seeded in a final volume of 0.5 ml in 24-well plates, infected with L.major pro-
mastigotes at 15:1 parasite to BMDM ratio, washed and incubated at 37°C for 30 min in com-
plete RPMI medium containing CpG ODN (15 μg/ml). PHMB, CpG ODN or PHMB/CpG
ODN polyplexes were added to the pre-activated or control cells and further incubated for
48 h. The supernatants were collected and IL-6, IL-10, IL-4 or TNF-α (Biosciences, Wiesbaden,
Germany) concentrations were measured by sandwich ELISA while IL-12p70 was measured by
using the IL-12p70 ELISA Ready-SET-Go kit from eBioscience according to the suppliers'
instructions.
Statistical analysis
Normalization and percentage calculations were based on mean fluorescence intensity (MFI)
of the treated cells as compared to the control in flow cytometry data analyses. The values are
given as mean ± standard error (SE). Statistical significance was determined by one sample t-
test (Microsoft Excel Software).
Ethics statement
All mice used in this experiment were kept under specific pathogen-free conditions and were
handled in strict accordance with the German Animal Welfare Act 2006 (TierSchG).The ani-
mal protocol was approved by the government of Lower Franconia, Germany with permission
number: 55.2–2531.01-26/12.
Results
Antileishmanial effects of PHMB and its proposed mechanisms of action
To investigate PHMB’s potential use as a topical therapeutic agent against CL, its antileishma-
nial activity against the extracellular form of L.major (promastigotes) was assessed using an
AlamarBlue cell viability assay [33]. PHMB effectively killed the promastigotes at sub-micro-
molar concentrations in a dose-dependent manner (S2 Fig). Determination of 50% inhibitory
concentrations (IC50 values) confirmed PHMB’s activity (IC50 = 0.41 μM) against L.major pro-
mastigotes in vitro, with higher potency than the current standard antileishmanial drugs used
in clinics (Table 1). PHMB was found to be 39-fold more potent than pentamidine, 69-fold
more potent than miltefosine and 1,000-fold more potent than paromomycin, the currently
recommended drug for treatment of CL. Visual examinations by light microscopy and TEM
clearly revealed morphological and behavioral changes to promastigotes following treatment
with PHMB (Fig 1). Furthermore, we investigated the bioactivity of PHMB against the intracel-
lular form of the parasite (amastigotes) in Leishmania-infected macrophages model. The IC50
value of PHMB against intracellular amastigotes was 4 μM, suggesting that the potency of
PHMB is lower against amastigotes relative to promastigotes.
To determine the level of pathogen/host selectivity of PHMB, we measured its cytotoxicity
against primary bone marrow-derived macrophages (BMDM), keratinocytes and 293T epithe-
lial cells using an AlamarBlue assay. The IC50 values obtained indicate that PHMB is about 6.5
fold more toxic against BMDM (IC50 = 4 μM) than 293T epithelial cells (IC50 = 26 μM). More-
over, PHMB killed 50% of keratinocytes at 6.6 ± 3.5 μM. The results show that keratinocytes
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are more sensitive to PHMB relative to 293T epithelial cells but less sensitive than BMDM.
Although PHMB is currently being safely used for several purposes in clinics and industries,
our results showed that PHMB has poor selectivity between amastigotes and BMDM with a
selectivity index of 1 (Table 1). Of course, it is important to consider that these values are for
cells grown in culture.
Encouraged by the potency of PHMB against L.major promastigotes, we investigated its
underlying mechanism(s) of action. Literature mining suggested that PHMB’s microbe-selec-
tive toxicity is due to preferential disruption of microbial membranes over mammalian mem-
branes [38,39]; it is believed to specifically interact with acidic phospholipids of microbial
pathogens, whereas the neutral phospholipids in mammalian cell membranes are only margin-
ally affected [38,40]. We hypothesized that PHMB also kills L.major parasites by this mecha-
nism, and tested the effects of PHMB on the membrane integrity of the promastigotes by using
propidium iodide (PI), a dye that can enter the parasite and stain DNA only after loss of mem-
brane integrity. After incubating promastigotes with 2 μM PHMB for 30 min, more than 20%
of the parasite population was stained by PI and staining increased at later time points (Fig
2A). We repeated the dye exclusion assay using YO-PRO-1 dye according to the manufactur-
er’s instructions, and the results showed similar time-dependent permeabilization (Fig 2B).
Therefore, PHMB damaged the membrane integrity of parasites in a time-dependent manner
and permeabilized parasites were observed within 30 minutes, supporting the hypothesis that
PHMB disrupts parasite membranes.
During our TEM ultrastructure analysis, we consistently observed condensation of parasite
nuclei after incubation with 2 μM PHMB for 24─48 h (Fig 1). Moreover, PHMB’s mechanism
of bactericidal action has been associated with its strong and cooperative interaction with
nucleic acids in vitro [41]. This led us to consider that PHMB’s parasite killing mechanism(s)
may also involve binding to DNA inside parasites. To test this possibility, promastigotes were
treated with 2 μM PHMB for 48 h, stained with Hoechst 33342 and examined by confocal and
fluorescence microscopy. The results indicated that PHMB bound, condensed and disrupted
chromosome structures (Fig 2C). This interpretation of the cellular effects would require poly-
mer entry into parasites and also strong PHMB binding to parasite genomic DNA (gDNA). To
test parasite entry, L.major promastigotes were incubated with a derivative of PHMB that was
covalently tagged with fluorescein isothiocyanate (FITC) at 0.35 μM (sub-IC50). The results
confirm that parasites take-up PHMB-FITC, and the polymer distributes into nuclei, where it
could interact with chromosomes (Fig 3A). To test chromosome binding, we used isolated
Table 1. Antileishmanial and cytotoxic effects of PHMB and PHMB/DNA polyplexes. The tables show antileishmanial efficacy, cytotoxicity and selectiv-
ity of the compounds. The IC50 values and/or selectivity index (SI) of the compounds as compared to standard antileishmanial drugs are shown. The table val-
ues are the average IC50 values of 3–6 independent experiments for each compound. IC50 = minimum concentration of the substances required to kill 50% of
the population; SI = mean IC50 against BMDM /mean IC50 against L.major amastigotes; ND = not determined.
Substances IC50 (μM) IC50 (μM) IC50 (μM) SI
promastigotes BMDMs amastigotes amastigotes
PHMB 0.41 ± 0.25 4± 0.7 4 ± 0.65 1
CpG ODN > 150 >150 >150 ND
PHMB/CpG (1:2 w/w) 2.54 ± 0.5 134 ± 40.2 1.12 ± 0.23 119.4
PHMB/CpG (1:1 w/w) 2.2 ± 0.28 50 ± 10.4 2. 82 ± 2.8 17.7
PHMB/CpG (2:1 w/w) 1.45± 0.33 33 ± 9.5 1± 0.55 15.89
Paromomycin >500 >900 1500 ± 112.5 ND
Miltefosine 28.33 ± 5.2 75.6 ± 10.9 54 ± 8.1 1.4
Pentamidine 16.19 ± 3.1 127.6 ± 24 6.38 ± 2.4 20
Amphotericin B 0.42 ± 0.5 > 21 0.099 ± 0.05 >208
doi:10.1371/journal.pntd.0004041.t001
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Fig 1. Effects of PHMB on L.majormorphology and behavior. (b and d) TEM images of L.major
promastigotes (right) showing morphological changes such as shrinkage, extensive cytoplasmic
vacuolization (V), marked loss of cytosolic contents and condensed nucleus (N). Images b and d were taken
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after treatment with 2 μMPHMB for 48 and 24 h, respectively. (a and c) The untreated controls (left) show
normal elongated morphology of promastigotes with intact and clear distinct kinetoplast (kDNA), N,
mitochondrion (M), lipid vacuoles (LV) and glycosome (G). (e-h) Light microscopy images showing
morphological and behavioral changes (no more clamp formation as indicated by arrowheads) after
treatment with 2 μMPHMB for 24 h. Scale bars = (a) 1.1 μm, (b) 0.6 μm, (c and d) 0.25 μm, (e and f) 7.5 μm
and (g and h) 25 μm.
doi:10.1371/journal.pntd.0004041.g001
Fig 2. Mechanism(s) of action of PHMB on L.major promastigotes. PHMB disrupted membrane integrity and condensed DNA in L.major promastigotes.
Representative FACS histogram (a) propidium iodide (PI) and (b) YO-PRO-1dye staining of promastigotes after treatment with 2 μMPHMB for indicated time
points, showing time-dependent effect of PHMB on the membrane integrity. Heat-killed promastigotes and amphotericin B at 2 μM concentration were used
as positive controls. (c) Fluorescent microscopy analysis showing condensed and damaged DNAmaterials of L.major promastigotes after treatment with
PHMB at 2 μM for 48 h as compared to the mock control (distilled water). Scale bars = 5 μm.
doi:10.1371/journal.pntd.0004041.g002
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genomic DNA (gDNA) from L.major and an electrophoretic mobility shift assay (EMSA).
Clear migration retardation confirmed that PHMB and gDNA form polyplexes at relative
weight ratios 0.25, and, thus, may also bind chromosomal DNA within parasites (Fig 4A).
We next considered how PHMB selectively condenses or disrupts parasite chromosomes
without affecting host DNA. To investigate the cellular localization(s) of PHMB, we used its
fluorescent version (PHMB-FITC). BMDM cells were incubated with 1 μM PHMB-FITC,
counter stained with Hoechst 33342, and internalization was investigated using fluorescence
and confocal laser scanning microscopy. The data show that PHMB readily enters BMDMs but
localizes in the cytoplasm without apparent entry into nuclei in mammalian cells, indicating
Fig 3. Cell localization of PHMB-FITC in promastigotes and BMDM.Confocal images showing uptake of PHMB-FITC by (a) promastagotes and (b)
BMDM. Note apparent nuclear exclusion in BMDM cells but not parasites, scale bars = 10 μm.
doi:10.1371/journal.pntd.0004041.g003
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failure to transit across the nuclear envelope (Fig 3B). Therefore, intracellular localization of
PHMB appears to differ in BMDMs and parasites, and PHMB gains access to parasite chromo-
somes but not host macrophage chromosomes.
PHMB is a novel non-viral carrier of CpG oligonucleotides
Two major observations encouraged us to hypothesize that PHMB in combination with immu-
nomodulatory nucleic acids could be used as parallel host- and pathogen-directed killing of an
intracellular L.major. Primarily, we knew that it binds genomic DNA of L.major parasites
forming PHMB/gDNA complexes. Moreover, PHMB has been used as an siRNA transfection
vehicle in hybrid form with iron oxide [42]. To test whether nucleic acid delivery could be
improved using PHMB, CpG ODN was selected as a model immunomodulatory nucleic acid
molecule. CpG ODN is a potent immune modulator that activates macrophages and dendritic
Fig 4. PHMB/DNA interactions and physicochemical characterization of polyplexes. Formation of PHMB/DNA polyplexes confirmed by 1% agarose
gel, TEM and color change. (a) PHMB/gDNA polyplexes, (b) TEM picture showing PHMB/CpG ODN polyplexes formation at 2:1 ratio, (c) PHMB/CpG ODN
polyplexes, (d) temporary turbidity change during PHMB/CpGODN complexation, (e) PHMB/CpG-R polyplexes and (f) the same gel (e) with fluorescence
measurement of CpG-R. With the exceptions of negative control and PHMB alone, all wells contained equal amounts (weight) of DNA with various
concentrations of PHMB. M represents 2-Log DNA ladder (0.1–10.0 kb, New England Biolabs) and N represents water used as a negative control. All
indicated PHMB/DNA ratios are in relative weight (w/w). Indicates two month old PHMB/CpG ODN polyplexes. Scale bar = 300 nm.
doi:10.1371/journal.pntd.0004041.g004
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cells to kill intracellular L.major parasites [43]. We reasoned that combinations of PHMB and
CpG ODN could potentially kill parasites directly through parasite membrane and chromo-
some disruption and indirectly through modulation of host immunity. If successful, such dual
host- and pathogen-directed effects could improve potency. In this context, a range of PHMB/
CpG ODN polyplex formulations were prepared and characterized, and their bioactivities were
evaluated and compared to the free components.
Before evaluating the potential use of PHMB as a safe and effective carrier for nucleic acids,
we first wanted to test whether PHMB binds CpG ODN to form stable nanocomplexes. TEM
results showed that there is complex formation between PHMB and CpG ODN at 2:1 ratio (Fig
4B). Our EMSA experiments showed that PHMB retards CpG ODNmobility at relative weight
ratios 0.25 (Fig 4C). Following addition of an excess of PHMB to CpG ODN, we also
observed an instant reaction that converted colorless PHMB and CpG ODN in solution to a
temporal milk-like appearance, suggesting electrostatic interactions between PHMB and CpG
ODN and complex formation (Fig 4D). Consistent with complex formation, the ODN in the
presence of PHMB showed migration retardation when analyzed by an EMSA. To more clearly
visualize oligo mobility changes, the same CpG ODN was labeled with rhodamine red at 3’ ter-
mini (CpG-R), and the results confirmed retarded electrophoretic mobility and retention of
CpG ODN in the wells (Fig 4E and 4F).
We next characterized the size and surface charge of complexes using DLS and ELS. These
analyses indicated particles of highly reproducible sizes: 310.9 ± 30.5 nm and 285.3 ± 15.0 nm
at relative weight ratios of 2:1 and 1:1, respectively (Table 2). The PDI values of the polyplexes
were less than 0.3, indicating a narrow size distribution. To assess the stability of the polyplexes,
their zeta potential was measured by ELS and was found to be + 33.3 ± 1.1 mV (ratio 2:1) and
—18.77 ± 0.4 mV (ratio 1:1), and dependant on the chosen ratio of PHMB and CpG ODN
(Table 3). As expected, higher PHMB to CpG ODN ratios resulted in polyplexes with higher
positive relative zeta potentials. The data show that PHMB/CpG ODN complexes are moderate
stable at 2:1 ratio, whereas they may not be stable at a 1:1 ratio. To evaluate stability over time,
PHMB/CpG ODN poylplexes were prepared and kept at 4°C for two months before their phys-
icochemical nature were again characterized by TEM and EMSA. Similar results were obtained
and, thus, confirmed the stability of the polyplexes over time at 2:1 ratio (Fig 4B and 4C
Table 2. Dynasore rescues killing of L.major amastigotes inside macrophages. Dynasore inhibited killing of the intracellular L.major amastigotes and
promastigotes by PHMB or PHMB/CpGODN polyplexes. Values are the average of two independent experiments and the values are given as mean ± SE.
The concentration values given are for PHMBwithin polyplexes.
Substances IC50 (μM) amastigotes IC50 amastigotes + dynasore (μM) IC50 (μM) promastigotes IC50 promastigotes + dynasore (μM)
PHMB 4 ± 0.7 8.1 ± 2 0.41 ± 0.25 0.697 ± 0.85
PHMB/CpG (1:2) 1.12 ± 0.23 >14.2 2.54 ± 0.5 4.8 ± 0.94
PHMB/CpG (1:1) 2.82 ± 2.8 >14.2 2. 2 ± 0.28 3.93 ± 0.82
PHMB/CpG (2:1) 1 ± 0.6 >14.2 1.45 ± 0.33 2.61 ± 0.41
Dynasore (80 μM) No activity No activity No activity No activity
doi:10.1371/journal.pntd.0004041.t002
Table 3. Physicochemical characterization of PHMB/CpGODN nanopolyplexes. The table shows particle size and zeta potential determination by
using DLS and ELS with their PDI. The table summarizes the results of three independent experiments. Size distribution and zeta potential measurements
were performed using Millipore water and ISA water (0.15M KCl), respectively.
Ratio of PHMB/ CpG ODN (w/w) Particle size (nm) Polydispersity index (PDI) Zeta potential (mV)
2:1 310.9 ± 30.5 0.222 ± 0.04 + 33.3 ± 1.1
1:1 285.3 ± 15.0 0.260 ± 0.02 - 18.77 ± 0.4
doi:10.1371/journal.pntd.0004041.t003
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indicated by1). To quantify the strength and specificity of the interactions between the two
molecules, we used isothermal titration calorimetry (ITC). The results show that PHMB can
strongly interact with CpG ODN to form polyplexes, confirming its binding affinity towards
DNA. The detailed thermodynamic parameters indicate sequential binding between PHMB
and CpG ODN (Fig 5). The ITC data show that the reaction enthalpy of the PHMB/CpG ODN
binding was initially exothermic (-18.37 kcal/mol), indicating a strong electrostatic interaction
between the negatively charged phosphate backbone of CpG ODN and the cationic charged
polymer PHMB. The exothermic signals declined during the course of titration and were
found to plateau at molar ratio of 1:1 of both binding partners. Finally, the TEM results also
confirm nanopolyplex formation between PHMB and CpG ODN, and further suggest a pre-
dominantly spherical morphology for the polyplexes, rather than cylindrical or rod forms (Fig
4B). Taken together, the results confirmed that there is strong electrostatic interaction between
PHMB and CpG ODN that leads to formation of moderate stable polyplex nanoparticles.
We next tested the potential to use PHMB as a safe and effective delivery vehicle for CpG
ODN. We characterized the polyplexes by measuring uptake efficiency, cytotoxicity, anti-para-
sitic efficacy and their immune modulating activity relative to the free components. The uptake
efficiency of CpG-R in the polyplex form was enhanced about 15-fold relative to the free form,
while the uptake of PHMB as a polyplex was not enhanced, confirming that PHMB can deliver
DNAmolecules into macrophages (Fig 6). Because PHMB and CpG incorporation into poly-
plex condensates may quench the mean fluorescence of PHMB-FITC or CpG-R, these uptake
measurements may underestimate delivery. To learn more about the mechanism of entry, we
investigated their uptake properties into macrophages. Confocal microscopy and flow cytome-
try results showed that PHMB-FITC is readily taken up by macrophages in a time-dependent
Fig 5. Physicochemical characterization of PHMB/CpGODN nanopolyplexes. The figures show quantitative measurements of the strength of
interaction between CpG ODN and PHMB by ITC with the corresponding thermodynamic parameters: binding affinity (Ka), enthalpy changes (ΔH) and
entropy changes (ΔS). (a) Raw data generated by ITC, (b) and (c) analyzed ITC data using two data analysis and plotting tools: Origin and SigmaPlot,
respectively.
doi:10.1371/journal.pntd.0004041.g005
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manner (Figs 3B and 6A). In contrast, when the PHMB-FITC was incubated with BMDM at
4°C under equivalent cell culture conditions, uptake was strongly reduced (87%) (Fig 7A), indi-
cating that the predominant uptake mechanism of PHMB-FITC by BMDM is via an energy-
dependent mode, which is likely to be endocytosis. To identify the specific endocytosis path-
way(s) involved, a wide range of selective endocytosis inhibitors were employed [32]. Briefly:
we used: 1) wortmannin, a potent inhibitor of phosphatidylinositol kinase (PI3K) that is com-
monly used as inhibitor of macropinocytosis, 2) cytochalasin D, which blocks the actin poly-
merization and is commonly used as an inhibitor of phagocytosis, 3) dynasore, an inhibitor of
dynamin-dependent endocytosis, 4) chlorpromazine hydrochloride, which inhibits a Rho
GTPase that is essential for the formation of clathrin-coated vesicles in clathrin-dependent
endocytosis, and 5) ikarugamycin, an inhibitor of clathrin coated pit-mediated endocytosis.
Cells were pre-incubated with specific endocytosis inhibitors for 30 min before exposure to
PHMB-FITC, the polyplexes, dextran or transferrin, followed by either incubation at 4°C or
37°C for 4 h. The results show that only dynasore, a cell-permeable small molecule that inhibits
dynamin GTPase activity needed for dynamin-dependent endocytosis, effectively inhibited the
uptake of PHMB-FITC (80% inhibition) (Fig 7A). Similar results were obtained for
PHMB-FITC/CpG ODN and PHMB/CpG-R polyplexes (Figs 7B and S3), suggesting that the
uptake pathways of PHMB by BMDM is not affected by a processes of polyplex formation.
However, dextran and transferrin were effectively inhibited by cytochalasin D and chlorproma-
zine hydrochloride but not by dynasore. Taken together, the results show that the uptake
mechanisms of PHMB-FITC and its polyplexes were predominantly via dynamin-dependent
endocytosis.
We next assessed cytotoxicity against the host cells. Surprisingly, the results showed that
IC50 values of the polyplexes were much higher (50 ± 10.4 4 μM and 33 ± 9.54 μM at 1:1 and
2:1 ratios, respectively) against BMDMs than the PHMB alone. Similarly, the toxicity of
PHMB/CpG ODN polyplexes showed much higher IC50 values (185 ± 22.5 and 90.3 ± 23.5 at
1:1 and 2:1 ratio, respectively) against 293T epithelial cells than PHMB alone. The results indi-
cate that the polyplexes have drastically reduced toxicity against host cells as compared to free
PHMB. Similarly, we checked the cytotoxicity of the polyplexes against L.major promastigotes
and the results show lower efficacy as compared to free PHMB, and CpG ODN alone did not
show activity (Table 1). The cationic nature of polymers (higher positive zeta potential) is often
associated with toxicity against host cells and decationizing is expected to reduce toxicity [44].
As expected, the toxicities of the polyplexes against BMDM and 293T cells increased as the rel-
ative weight ratio of PHMB:CpG ODN was increased (Table 1). These results are consistent
Fig 6. Cellular uptake of PHMB and CpGODN, and their polyplxes by BMDM. The overlay histograms show time dependent uptake of (a) PHMB-FITC
and (b) PHMB-FITC/CpGODN polyplexes into macrophages. Whereas (c) shows uptake of CpG-R by BMDM as polyplex form compared to its free form.
The histograms are representative of three independent experiments.
doi:10.1371/journal.pntd.0004041.g006
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with our zeta potential data showing that increasing PHMB/CpG ODN ratios increased poly-
plex positive charge (Table 3).
We then determined leishmanicidal effects of PHMB and CpG ODN in polyplex and free
forms using BMDM infected with the luciferase-transgenic L.major strain. The polyplexes dis-
played enhanced antileishmanial activity against intracellular amastigotes while increasing
selectivity many fold (Table 1). We hypothesized that enhanced antileishmanial activity was
due to increased host cell delivery. If this was the case, blockage of the uptake pathway using
dynasore would suppress PHMB’s intracellular killing of amastigotes. Accordingly, we deter-
mined the efficacy of PHMB or its polyplexes against intracellular amastigotes in the presence/
absence of dynasore. The results show clearly that dynasore inhibits PHMB-mediated killing of
amastigotes (Table 2). In the presence of dynasore (80 μM), the IC50 value of PHMB against
the intracellular amastigotes was increased by two fold and the polyplexes were completely
inactive until the maximum dose tested (14.2 μM) as compared to the polyplexes without dyna-
sore (1–2.28 μM). Similarly, dynasore inhibited the antileishmanial effects of PHMB and the
polyplexes against promastigotes. To learn more about the effect of dynasore on PHMB medi-
ated killing of promastigotes, we investigated the mechanism by which the promastigotes take
up PHMB. We used sub-IC50 doses of PHMB-FITC (0.35 μM) and the same inhibitors used
earlier with BMDMs. Surprisingly, the results showed that dynasore inhibited the uptake of
PHMB-FITC into promastigotes by more than 98% while other inhibitors did not significantly
alter uptake (S4 Fig). Dynasore alone did not display cytotoxicity against either amastigotes or
promastigotes (Table 2). Therefore, dynasore rescued the parasites from the intracellular antil-
eishmanial effects of PHMB by blocking polymer uptake into macrophages, further confirming
its intracellular killing potential, consistent with our evidence of a DNA-level mechanism of
action. Moreover, the results suggest that dynasore also blocks the uptake of PHMB by
Fig 7. Cellular uptake of PHMB-FITC and PHMB-FITC/CpGODN polyplexes and effects of selective endocytosis inhibitors. The bar graphs show the
effects of different inhibitors and temperature on cellular uptake of (a) PHMB-FITC, (b) PHMB-FITC/CpGODN polyplexes, (c) dextran/FITC used as positive
control to exclude the effect of FITC that might interfere with the cellular uptake mechanisms of PHMB and (d) alexa-448-labeled transferrin used as positive
control for clathrin-dependent endocytosis. Normalized MFI values of three independent flow cytometry experiments are shown and the values are given as
mean ± SE.
doi:10.1371/journal.pntd.0004041.g007
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promastigotes and, consequently reduced the antileishmanial effects. Taken together, the
results suggest that PHMB is an effective antileishmanial compound and a nucleic acid entry-
promoting vehicle for host- and pathogen-directed therapy.
Finally, to assess whether PHMB has immunomodulatory properties and whether polyplex
formation affects the immunomodulatory properties of CpG ODN, the concentrations of sev-
eral key cytokines were measured by enzyme-linked immunosorbent assays (ELISA) taken
from supernatants of co-cultured BMDM. For free CpG ODN, production of all cytokines
tested increased with increasing doses (Fig 8). We were not able to obtain reliable measures of
IL-4 and TNF-α in cells treated with polyplexes or the free components (S2 Table). We also
observed that PHMB alone stimulated the production of proinflammatory cytokines such as
IL-6, IL-10 and IL-12 by activating macrophages (S5 Fig). Moreover, based on the IL-6, IL-12
and IL-10 measurements, the polyplexes generally showed higher immune stimulation capacity
as compared to free CpG ODN. This suggests that the polyplex components are bioactive after
delivery into BMDMs; in other words, PHMBmust release the CpG ODN from the polyplexes
inside BMDM.
Fig 8. Effects of CpG ODN and PHMB/CpGODN polyplexes on cytokine production by BMDM. The bar graphs show the levels of (a-b) IL-6, (c-d) IL-10
and (e-f) IL-12 production after CpGODN or PHMB/CpGODN polyplexes were added to BMDM that had been pre-activated with CpG ODN (15 μg/ml) for 30
min and further incubated for 48 h. Controls were cells without any pre-stimulation and the 0 μM doses were cells pre-stimulated by CpG ODN but without any
further stimulation by CpG ODN or the complex. The concentrations shown for the polyplexes represent the dose of PHMB and the concentrations of CpG
ODN are half of the indicated doses. The error bars show standard errors from three independent experiments.
doi:10.1371/journal.pntd.0004041.g008
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Discussion
Leishmaniasis therapy relies on only a few chemotherapeutic agents, all of which lack appropri-
ate efficacy, safety and affordability. Many drugs used as antiparasitics were repositioned from
other disease areas [14], and this strategy seems appropriate for leishmaniasis, where a very
low cost of goods is required. Here we demonstrate that the long-established antimicrobial
polymer PHMB is a potent antileishmanial candidate drug for topical applications against CL.
PHMB is more potent than the current standard antileishmanial drugs in vitro and may pro-
vide additional benefits through wound healing, immune modulation and cellular delivery of
complementary drugs.
PHMB is a very inexpensive compound (about $10-50/kg) that has been widely used in clin-
ics, homes and industry as a disinfectant and antiseptic, with excellent tolerance for over 50
years worldwide [40,45–47]. It has a solid safety record and is widely considered to be useful in
wound care [29,48]. As typical for cationic polymers, cell toxicity is observed at high concentra-
tions. PHMB toxicity was found to be unexpectedly high against BMDM, but was greatly
reduced when complexed with ODN, presumably due to charge complexation/shielding, while
retaining antileishmanial effects (Table 1). Thus, PHMB may be repositioned and potentially
used as an effective topical drug against CL, following appropriate clinical trials, and complexa-
tion with immunomodulatory CpG oligos may provide additional benefits.
Our results suggest that PHMB directly kills parasites via a dual mechanism involving both
permeabilization of parasite membranes and selective condensation and disruption of parasite
chromosomes. Recently, it has been shown that PHMB readily enters diverse bacterial species
and kills through chromosomal condensation (Chindera et al., submitted). Similarly, our
results reveal that PHMB condenses or damages parasite chromosomes, but does not enter
macrophage nuclei. Thus, the finding helps to explain how PHMB kills parasites without simi-
lar damage to host cells.
Successful chemotherapy of infectious diseases caused by intracellular pathogens, including
L.major, involves modulation of host immunity for host-directed treatments. It has been
shown that the recommended antileishmanial drugs have immunomodulatory properties and
exert their effect in part via host immunomodulation [49,50]. Thus, a combination therapy
comprising components that can directly kill the pathogen as well as activate host immune sys-
tems are attractive. Nucleic acids such as CpG ODN have potential applications both as adju-
vants and nonspecific immune modulators by triggering immunity against intracellular
pathogens like L.major [43]. They also hold great promise for therapy against many diseases as
mediators of RNA silencing and vaccination. However, medical applications are severely hin-
dered by their instability in biological fluids and poor cellular uptake [51]. Also, an efficient
and safe delivery of nucleic acid-based immune modulators is a key challenge. Complexing
nucleic acids with clinically compatible polymers to form nanoparticles could overcome the
delivery challenges by improving passage across physiological or cell barriers. In the context of
host- and pathogen-directed therapy, we investigated the nucleic acid delivery potential of
PHMB as well as the overall synergistic effect of a combined therapy comprising PHMB and
CpG ODN complexes against CL. PHMB and CpG ODN form self-assembled nanostructures
that are readily taken up by macrophages, increasing the uptake efficiency of nucleic acids and
increasing the potency and selectivity of PHMB against the parasites. In principle, polyplex for-
mulation could improve delivery and provide sustained release.
The potential antileishmanial effects of PHMB are threefold. First, it can accelerate wound
closure, thus improving the cosmetic outcome of CL and preventing secondary bacterial and/
or fungal infections which often delay wound healing in CL patients [52]. Second, it can
directly kill lesion-causing parasites. Third, the antileishmanial effects of PHMBmay be further
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facilitated by its ability to deliver immunomodulatory agents such as CpG ODN. The discovery
of PHMB-nucleic acid interactions and formation of nanopolyplexes for efficient delivery into
macrophages may have vast applications beyond the initial objectives of this study, including
therapy for other intracellular pathogens or non-infectious diseases.
Supporting Information
S1 Fig. Structure of PHMB.
(TIF)
S2 Fig. Dose-dependent antileishmanial activity of PHMB against L.major promastigotes.
The error bars show the standard error of three independent experiments.
(TIF)
S3 Fig. CpG ODN delivery into macrophages using PHMB. The cellular uptake potential of
(a) PHMB/CpG-R and (b) PHMB-FITC/CpG ODN polyplexes, and inhibition by dynasore.
Free PHMB-FITC, PHMB-FITC/CpG ODN and PHMB/CpG-R polyplexes were efficiently
blocked by dynasore. Based on their MFI, the uptake of CpG-R was enhanced by about 15
folds as polyplex form compared to its free form.
(TIF)
S4 Fig. PHMB-FITC uptake into promastigotes and the effects of selective endocytosis
inhibitors. The bar graphs show the effects of different inhibitors on blocking the uptake of
PHMB-FITC by promastigotes. Normalized mean fluorescence intensity (MFI) values of three
independent flow cytometry experiments are depicted as mean ± SE.
(TIF)
S5 Fig. Effects of PHMB on cytokine production by BMDM.
(TIF)
S1 Table. PHMB:CpG ODN and PHMB concentrations presented in various units. (a)
Shows the concentration of free PHMB and (b-d) show concentrations of the polyplex for each
PHMB to CpG ODN ratio.
(PDF)
S2 Table. Measurements of IL-4 and TNF-α production. Calculated concentrations of (a) IL-
4 and (b) TNF-α production in ng/ml after treated with PHMB (rows 3 and 4), CpG ODN
(rows 5 and 6) or PHMB/CpG ODN polyplexes (rows 7 and 8) at different concentrations.
Rows 1 and 2 are serially diluted (1:1) standards. Rows 9A and 10A are controls.
(TIF)
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